40547-06-6

Basic information

• Product Name: 5(4H)-Oxazolone, 2-(2-chlorophenyl)-4-(phenylmethylene)-
• Synonyms: 5(4H)-Oxazolone,2-(2-chlorophenyl)-4-(phenylmethylene);4-benzylidene-2-(2-chloro-phenyl)-4H-oxazol-5-one
• CAS NO: 40547-06-6
• Molecular Formula: C16H10ClNO2
• Molecular Weight: 283.714
• Mol File: 40547-06-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5(4H)-Oxazolone, 2-(2-chlorophenyl)-4-(phenylmethylene)-(CAS DataBase Reference)
• NIST Chemistry Reference: 5(4H)-Oxazolone, 2-(2-chlorophenyl)-4-(phenylmethylene)-(40547-06-6)
• EPA Substance Registry System: 5(4H)-Oxazolone, 2-(2-chlorophenyl)-4-(phenylmethylene)-(40547-06-6)

Safety Data

• Hazardous Substances Data: 40547-06-6(Hazardous Substances Data)

Upstream product

• 16555-60-5 2-chlorohippuric acid 
• 100-52-7 benzaldehyde 

Downstream Products

• 89242-09-1 1-(2-chlorophenyl)-3-isoquinolinecarboxylic acid 

Relevant articles and documents

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

The present invention relates to novel quinoxaline, quinazoline and phthalazine derivatives as well as multimeric derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds for the treatment and prevention of brain damage resulting from brain injury, especially secondary brain damage due to traumatic brain injury (TBI). The compounds of the invention are also useful in treating and preventing neurodegenerative diseases.